ODC1/SRM knockdown did not alter time for tumor formation (Figure 2O, left panel) or tumor eradication (Figure 2O, middle panel), but significantly increased time for tumor recurrence (Figure 2O, right panel), indicating that ODC1/SRM knockdown decreases numbers of BCSCs in response to paclitaxel treatment, which is a major cause of tumor relapse. Here, ODC1 is linked to neoplasm.